A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Debt-to-EBITDA or its related term are showing as below:
MEX:LABB'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.29 Med: 2.14 Max: 2.66
Current: 2.3
During the past 13 years, the highest Debt-to-EBITDA Ratio of Genomma Lab InternacionalB de CV was 2.66. The lowest was -5.29. And the median was 2.14.
MEX:LABB's Debt-to-EBITDA is ranked worse than 59.74% of 688
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs MEX:LABB: 2.30
Genomma Lab InternacionalB de CV (MEX:LABB) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Genomma Lab InternacionalB de CV Debt-to-EBITDA Related Terms
Genomma Lab InternacionalB de CV Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Debt-to-EBITDA Chart
MEX:LABB vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Genomma Lab InternacionalB de CV (MEX:LABB) has a Debt-to-EBITDA of 2.21 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Genomma Lab InternacionalB de CV. This is near median its historical median of 2.14. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #411 out of 688 companies in the Drug Manufacturers industry, placing it in the top 59.7%.
Is Genomma Lab InternacionalB de CV's Debt-to-EBITDA too high?
Genomma Lab InternacionalB de CV's current Debt-to-EBITDA of 2.21 is near median its 10-year median of 2.14. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Genomma Lab InternacionalB de CV's value of 2.21 is 31.5% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #411 out of 688 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #411 out of 688 companies for Debt-to-EBITDA. This places Genomma Lab InternacionalB de CV in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Genomma Lab InternacionalB de CV's value of 2.21 is 31.5% above this benchmark. While the company's 10-year median is 2.14 vs. the industry median of 1.68, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 688 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Debt-to-EBITDA of 2.21 is 31.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Genomma Lab InternacionalB de CV. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Debt-to-EBITDA is 2.21, which is near median its own 10-year median of 2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.65, compared to a current price of MXN14.98 — trading 15.1% below its estimated fair value. The current Debt-to-EBITDA is 2.21, which is near median its 10-year median of 2.14 and 31.5% above the Drug Manufacturers industry median of 1.68. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Debt-to-EBITDA is 2.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN14.98 is trading 15.1% below its estimated GF Value™ of MXN17.65.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Debt-to-EBITDA: 2.21 (near median its 10-year median of 2.14)
GF Value™: MXN17.65 vs. price of MXN14.98 (15.1% below fair value)
Industry Position: 31.5% above the Drug Manufacturers median (#411 of 688)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
